Mesalamine for ulcerative proctitis: We are enrolling pediatric patients age 6-17 with proctitis for a study to test mesalamine suppositories (500mg once or twice daily). The study, sponsored by AXCAN Pharma, is a 6 week study long and includes a baseline visit flex sig, one out-patient follow-up visit and final visit flex sig (which is optional). Patients will be reimbursed $100. Patients will not be billed for any visits or tests performed as part of this study.
Colazal for ulcerative colitis: We will soon be enrolling pediatric patients age 5-17 with mild to moderate ulcerative colitis.